From virus to vaccination: a comprehensive review of Human Papilloma Virus (HPV) vaccine and introduction to India’s national HPV vaccination initiative

Cervical cancer is the fourth most common cancer in women worldwide, and India accounts for about 13% of the global burden. On 28 February 2026, India launched its first national human papillomavirus (HPV) vaccination programme, eight years after its National Technical Advisory Group on Immunisation (NTAGI) first recommended the vaccine’s inclusion in the Universal Immunisation Programme, and a decade after the 2009-10 Andhra Pradesh and Gujarat demonstration-project controversy that shaped India’s relationship with this vaccine afterward. This narrative review synthesises the evidence a national immunisation decision rests on, across six domains: HPV virology and vaccine pharmacology; global efficacy and immunogenicity trials from the first licensed vaccines through single-dose regimens; the safety evidence base, including the Scandinavian pharmacovigilance cohorts and India’s 2009-10 controversy; the introduction experience of eight national programmes (Australia, England, Sweden, Rwanda, Bhutan, Kenya, Japan, India); the cost-effectiveness evidence for HPV vaccination; and India’s vaccine-development and policy trajectory through the 2026 launch and the licensure of the indigenous Cervavac vaccine. We searched PubMed and Scopus and supplemented peer-reviewed evidence with independently verified grey literature; the full search strategies are in Supplementary File S1. Three independent single-dose datasets, an Indian cohort followed for 12–15 years, a Kenyan trial (KEN SHE), and a Costa Rican trial (ESCUDDO), together show high, concordant single-dose protection over the follow-up each has actually completed, and two Scandinavian pharmacovigilance cohorts with a combined study population exceeding four million, of whom just over half a million were vaccinated, found no safety signal warranting a policy change. Register data show observed cervical cancer reductions of 87% in England (girls offered the vaccine at age 12–13) and 88% in Sweden (women vaccinated before age 17); modelled projections suggest further reductions with sustained coverage. In our assessment, this evidence supports India’s 2026 programme on the vaccination decision itself. The evidence for the rollout’s specific design is more limited: the single-age cohort, the choice of an imported vaccine over the newly trialled indigenous Cervavac, and the eight-year gap between recommendation and launch are less directly supported by published evidence. We conclude that two priorities remain open: closing the screening gap (about 2% in NFHS-5, 2019-21, against a 70% WHO target; later programme data use a different indicator and denominator) and a funded, time-bound plan to move from GAVI-donated supply to domestic manufacture.

Infectious Agents and Cancer , article en libre accès, 2026

Voir le bulletin